Trial · NCT06029998
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
NCT06029998, Phase 2, Active not recruiting, University of Utah
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion. Trials, record NCT06029998. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06029998
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
- NCT number
- NCT06029998
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 22 participants, estimated
- Lead sponsor
- University of Utah
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Bortezomib
- First posted
- 2023-09-08
- Last updated
- 2026-07-07
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients achieving PSA decline of ≥ 30% from baseline will be considered a response. | Up to 6-8 cycles of treatment. Each cycle is 21 days. | To evaluate the antitumor activity of bortezomib in patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN deletion as assessed by prostate-specific antigen (PSA) 30% response rate. |
| Secondary | The proportion of patients achieving PSA decline of ≥ 50% (PSA50) compared to the baseline value prior to starting study treatment. | Up to 6-8 cycles of treatment. Each cycle is 21 days. | To assess the PSA 50% response rate in the study population. |
| Secondary | Duration of PSA response as defined as the interval of time from PSA decline of ≥ 50% to PSA progression as defined by PCWG3 criteria. | Until progression or end of study. Study anticipated to be about 4 years. | To assess duration of PSA response in the study population. |
| Secondary | PSA PFS as defined as the interval of time from study drug initiation to the time of PSA progression as defined by PCWG3 criteria. | Until progression or end of study. Study anticipated to be about 4 years. | To assess the PSA progression-free survival (PSA PFS) in the study population. |
| Secondary | ORR as defined as the proportion of patients with measurable disease achieving a confirmed partial response (PR) and complete response (CR) as assessed by PCWG3-modified RECIST | Until progression or end of study. Study anticipated to be about 4 years. | To assess the objective response rate (ORR) in the study population. |
| Secondary | DoR as defined as the interval of time from the date of initial documented response (PR or better per PCWG3-modified RECIST 1.1) to the time of progression, the start of a new therapy, or death from any cause. | Until progression or end of study. Study anticipated to be about 4 years. | To assess the duration of response (DoR) in the study population. |
| Secondary | rPFS as defined as the time from study drug initiation to the time of radiographic disease progression as assessed by PCWG3 modified RECIST 1.1 or death from any cause. | Until progression or end of study. Study anticipated to be about 4 years. | To assess radiographic progression-free survival (rPFS) |
| Secondary | PFS as defined as the time from study drug initiation to the time of disease progression (clinical or radiological as assessed by PCWG3 modified RECIST 1.1) or death from any cause. | Until progression or end of study. Study anticipated to be about 4 years. | To assess PFS in the study population. |
| Secondary | OS as defined as the time from study drug initiation until death from any cause. | Until end of study. Study anticipated to be about 4 years. | To assess overall survival (OS) in this study population. |
| Secondary | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type. | Until end of study. Study anticipated to be about 4 years. | To assess the safety of bortezomib in study population. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06029998
GET https://conductscience.org/api/trials/v1/NCT06029998/registered